Neuromyelitis Optica Treatment Analysis of 36 Patients

Show simple item record

dc.contributor.author Bichuetti, Denis Bernardi [UNIFESP]
dc.contributor.author Lobato de Oliveira, Enedina Maria [UNIFESP]
dc.contributor.author Oliveira, Daniel May [UNIFESP]
dc.contributor.author Souza, Nilton Amorin de [UNIFESP]
dc.contributor.author Gabbai, Alberto Alain [UNIFESP]
dc.date.accessioned 2018-06-15T13:56:00Z
dc.date.available 2018-06-15T13:56:00Z
dc.date.issued 2010-09-01
dc.identifier http://dx.doi.org/10.1001/archneurol.2010.203
dc.identifier.citation Archives Of Neurology. Chicago: Amer Medical Assoc, v. 67, n. 9, p. 1131-1136, 2010.
dc.identifier.issn 0003-9942
dc.identifier.uri http://repositorio.unifesp.br/11600/42648
dc.description.abstract Objective: To analyze treatment response in Brazilian patients with neuromyelitis optica.Design: Retrospective review.Setting: Neuroimmunology Clinic of the Federal University of Sao Paulo, Sao Paulo, Brazil.Patients: Thirty-six patients with relapsing-remitting optic-spinal disease; long, extending spinal cord lesions; and brain magnetic resonance images not meeting Barkhof criteria for multiple sclerosis, thus fulfilling the 1999 and 2006 criteria for neuromyelitis optica. Patients were followed up from 1994 to 2007.Main Outcome Measures: Relapses and accumulation of disability.Results: Mean follow-up time was 47.2 months and mean age at onset was 32.3 years. Sixty-four treatments were implemented in 36 patients, which included interferon beta, methotrexate, cyclophosphamide, prednisone, and azathioprine solely or plus prednisone. Patients who were treated with azathioprine or azathioprine with prednisone had a reduction in the occurrence of relapses and Expanded Disability Severity Scale score stabilization, as opposed to patients who received other treatments. Of the 4 patients who died, only 1 had received azathioprine treatment.Conclusion: Azathioprine as monotherapy or with prednisone seems to have reduced the relapse frequency and halted disability progression in the majority of patients treated, with minor and manageable adverse effects. en
dc.description.sponsorship Bayer Schering
dc.description.sponsorship Biogen Idec
dc.description.sponsorship Merck Serono
dc.description.sponsorship Teva Pharmaceuticals
dc.format.extent 1131-1136
dc.language.iso eng
dc.publisher Amer Medical Assoc
dc.relation.ispartof Archives Of Neurology
dc.rights Acesso aberto
dc.title Neuromyelitis Optica Treatment Analysis of 36 Patients en
dc.type Artigo
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.description.affiliation Univ Fed Sao Paulo, Dept Neurol & Neurocirurgia, BR-04039900 Sao Paulo, Brazil
dc.description.affiliationUnifesp Univ Fed Sao Paulo, Dept Neurol & Neurocirurgia, BR-04039900 Sao Paulo, Brazil
dc.identifier.doi 10.1001/archneurol.2010.203
dc.description.source Web of Science
dc.identifier.wos WOS:000282102800014



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account